Interferon beta-1a for brain tissue loss in patients at presentation with syndromes suggestive of multiple sclerosis: a randomised, double-blind, placebo-controlled trial
about
Neurodegeneration in multiple sclerosis: novel treatment strategiesImmunomodulators and immunosuppressants for multiple sclerosis: a network meta-analysisRecombinant interferon beta or glatiramer acetate for delaying conversion of the first demyelinating event to multiple sclerosisOptimizing treatment success in multiple sclerosisThe effect of disease modifying therapies on brain atrophy in patients with relapsing-remitting multiple sclerosis: a systematic review and meta-analysisCountry, sex, EDSS change and therapy choice independently predict treatment discontinuation in multiple sclerosis and clinically isolated syndromeTreatment with disease-modifying drugs for people with a first clinical attack suggestive of multiple sclerosis.Clinical use of brain volumetry.[Clinically isolated syndrome].Clinical relevance of brain volume measures in multiple sclerosis.Therapeutic strategies for relapsing-remitting multiple sclerosis: a special focus on reduction of grey matter damage as measured by brain atrophy.Treating relapsing-remitting multiple sclerosis: therapy effects on brain atrophy.Imaging of multiple sclerosis: role in neurotherapeutics.Brain atrophy in multiple sclerosis: therapeutic, cognitive and clinical impact.Interferon-beta1a for the treatment of multiple sclerosis.Subcutaneous interferon β-1a may protect against cognitive impairment in patients with relapsing-remitting multiple sclerosis: 5-year follow-up of the COGIMUS study.The puzzle of multiple sclerosis: gray matter finds its place.Treatment of early multiple sclerosis: the value of treatment initiation after a first clinical episode.Multiple sclerosis lesions: insights from imaging techniques.Efficacy of subcutaneous interferon β-1a on MRI outcomes in a randomised controlled trial of patients with clinically isolated syndromes.Shifting imaging targets in multiple sclerosis: from inflammation to neurodegeneration.Therapeutic strategies in childhood multiple sclerosisVolumetric MRI markers and predictors of disease activity in early multiple sclerosis: a longitudinal cohort study.Gray matter atrophy in multiple sclerosis: a longitudinal study.When to initiate disease-modifying drugs for relapsing remitting multiple sclerosis in adults?Glatiramer acetate in multiple sclerosis.A regional consensus recommendation on brain atrophy as an outcome measure in multiple sclerosis.The effect of disease-modifying therapies on brain atrophy in patients with clinically isolated syndrome: a systematic review and meta-analysis.The diagnosis and management of multiple sclerosis.Prognosis of multiple sclerosis: clinical factors predicting the late evolution for an early treatment decision.Neutralising antibodies to IFN-beta in patients with multiple sclerosis.Effects of interferon beta-1b on cognitive performance in patients with a first event suggestive of multiple sclerosis.Brain atrophy in multiple sclerosis: what we know and would like to know.Interferon-beta treatment for multiple sclerosis.Updates on clinically isolated syndrome and diagnostic criteria for multiple sclerosisBrain surface contraction mapped in first-episode schizophrenia: a longitudinal magnetic resonance imaging studyThe Effect of Dimethyl Fumarate on Cerebral Gray Matter Atrophy in Multiple Sclerosis.Determinants of interferon β efficacy in patients with multiple sclerosis.Advances in imaging to support the development of novel therapies for multiple sclerosis.Treatment update in multiple sclerosis.
P2860
Q22241472-D5081EB7-3AF0-4CD4-B490-FBB4F06C88E4Q24202108-7B2A4A29-6E6B-41E2-9CB0-BC0B101129CBQ24243043-32B1DA00-5A7A-4325-BF59-DBD835148022Q26771968-8FB46A35-DE63-41C9-8B70-CFB8DE6C3744Q26824991-091E8D03-F590-4C81-92F2-BB2C0EAC24E7Q28480907-FC4CE9A7-C473-48B5-B764-343F65C40A62Q30234672-DB2CCE93-4842-4EC3-86F0-C16A7B097232Q30582479-CBD3D260-110B-489B-95F3-FF85AF475F08Q30670868-4806BACF-432A-424A-B5D3-89E480B86DF4Q30738659-77430A51-35F0-49E4-A7E0-8A9FFE029749Q30869048-381EB471-4F26-469F-86F7-A7C44A65B684Q30965003-A2DCA1E6-8BF6-46EE-9438-3B765F465518Q30989935-A21A0AED-89A0-4026-8716-AB16E1937643Q31070072-BE5FFE4C-5714-42CF-991D-03E1B164A408Q31106233-D74A94B6-4CBD-42EA-A326-07BA1EF6716EQ31141962-0B646B71-19DF-440E-90EE-16523C11F242Q33352371-BDEA6DC0-B0D9-423B-B368-AD1078C953FBQ33500910-2431B332-062B-43E8-8D8B-F0003D28210EQ33505423-09F8D7A5-6ED4-4551-A054-48506B7F453FQ33658606-A86BBE96-E368-4300-B362-A076E9A8F32FQ34303664-F208641B-AC81-4E77-A8B0-95BFBC879680Q34409508-E58E3D9F-89EC-40AC-A3BB-7764AF9546E8Q34483022-6972C5E5-3ACE-409A-AA39-46A527A902FCQ34801849-45237864-C39D-431C-A905-883FDAF82950Q35374052-E2262D9C-12B5-4878-8753-1BF640DCF7B1Q36198583-DB8D1C8D-066C-44D1-A6DE-E6D1D2841218Q36202826-45D39E4D-D2CC-4527-9099-383BE5CE7EC1Q36211674-8267A8E2-9FC8-49D0-99D5-26551515CC45Q36228017-1D35CA99-D117-4429-BCD3-90D31E670A17Q36419573-5FD9D4F1-FDA8-4F70-B289-F43804AB4E73Q36541952-781357F8-B635-4612-AD70-987DF241BF39Q36613378-F867265B-850C-41B5-96C6-EB67DE07F117Q36722172-390E6AC9-4282-4917-ACB6-39BBE4D0BB5BQ36963178-D46C6AB7-376A-49B7-BABF-636357662364Q37052797-81EB587A-E1A5-42F0-AC99-DD6E983B9115Q37411410-67C73D03-1DC3-4C74-B214-E5CFFD2E753DQ37459099-792A3FB0-499D-4342-937B-860E378EBD82Q37848651-DDD4DD24-2937-4D31-8265-743B02CD0B1EQ37991519-2890E27B-BAAF-48F4-A5FE-93FDCD3529EDQ37996859-F82A1BDC-4B77-4EC7-8484-99D31B5AEF22
P2860
Interferon beta-1a for brain tissue loss in patients at presentation with syndromes suggestive of multiple sclerosis: a randomised, double-blind, placebo-controlled trial
description
article publié dans la revue scientifique The Lancet
@fr
im Oktober 2004 veröffentlichter wissenschaftlicher Artikel
@de
scientific article published in The Lancet
@en
wetenschappelijk artikel
@nl
наукова стаття, опублікована в жовтні 2004
@uk
ശാസ്ത്രപ്രബന്ധം
@ml
name
Interferon beta-1a for brain t ...... lind, placebo-controlled trial
@en
Interferon beta-1a for brain t ...... lind, placebo-controlled trial
@nl
type
label
Interferon beta-1a for brain t ...... lind, placebo-controlled trial
@en
Interferon beta-1a for brain t ...... lind, placebo-controlled trial
@nl
prefLabel
Interferon beta-1a for brain t ...... lind, placebo-controlled trial
@en
Interferon beta-1a for brain t ...... lind, placebo-controlled trial
@nl
P2093
P921
P1433
P1476
Interferon beta-1a for brain t ...... lind, placebo-controlled trial
@en
P2093
Frederik Barkhof
Giancarlo Comi
Marco Rovaris
Matilde Inglese
Nicola De Stefano
P304
P356
10.1016/S0140-6736(04)17271-1
P407
P577
2004-10-01T00:00:00Z